Pharmacokinetics of Lisdexamfetamine

Mechanism of Action

The American Academy of Pediatrics notes that lisdexamfetamine is a therapeutically inactive molecule until it undergoes hydrolysis in the blood to release d-amphetamine and L-lysine, with the conversion occurring through rate-limited hydrolysis, resulting in delayed absorption compared to immediate-release amphetamine formulations 1, 2
The prodrug design results in the prodrug being ingested orally and metabolized to be active, with alternative routes of administration not bypassing this requirement effectively 1, 2

The prodrug design of lisdexamfetamine provides sustained therapeutic coverage throughout the day with a single morning dose, eliminating the need for multiple administrations and ensuring consistent symptom control across daily activities. 3